Recent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Influenza Vaccines
— Real-world evidence (RWE) data estimate 19.8% relative vaccine effectiveness (rVE) of cell-based quadrivalent influenza vaccines (QIVc) versus standard egg-based quadrivalent vaccines (QIVe) in the prevention of test-confirmed influenza during the 2023/24 U.S. season for populations six months to 64 years.1 — Consistent rVE results were observed for pediatric, adult, outpatient and high-risk subgroups.1 — […]